BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 26866954)

  • 1. Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis.
    Mirembe BG; Kelly CW; Mgodi N; Greenspan S; Dai JY; Mayo A; Piper J; Akello CA; Kiweewa FM; Magure T; Nakabiito C; Marrazzo JM; Chirenje ZM; Riddler SA;
    J Acquir Immune Defic Syndr; 2016 Mar; 71(3):287-94. PubMed ID: 26866954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
    Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
    Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
    Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
    PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
    Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):177-182. PubMed ID: 28639995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of vitamin D and calcium supplementation on bone mineral density among Thai youth using daily HIV pre-exposure prophylaxis.
    Pornpaisalsakul K; Songtaweesin WN; Tepmongkol S; Wongharn P; Kawichai S; Suponsilchai V; Anugulruengkitt S; Puthanakit T;
    J Int AIDS Soc; 2020 Oct; 23(10):e25624. PubMed ID: 33040465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial.
    Stranix-Chibanda L; Tierney C; Sebikari D; Aizire J; Dadabhai S; Zanga A; Mukwasi-Kahari C; Vhembo T; Violari A; Theron G; Moodley D; George K; Fan B; Sommer MJ; Browning R; Mofenson LM; Shepherd J; Nelson B; Fowler MG; Siberry GK;
    PLoS One; 2021; 16(2):e0246272. PubMed ID: 33544759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM;
    JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study.
    Han WM; Wattanachanya L; Apornpong T; Jantrapakde J; Avihingsanon A; Kerr SJ; Teeratakulpisarn N; Jadwattanakul T; Chaiwatanarat T; Buranasupkajorn P; Ramautarsing R; Phanuphak N; Sunthornyothin S; Ruxrungtham K; Phanuphak P;
    PLoS One; 2020; 15(3):e0230368. PubMed ID: 32210458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone changes with candidate PrEP regimens containing tenofovir disoproxil fumarate and/or maraviroc and/or emtricitabine in US men and women: HPTN 069/ACTG A5305.
    Brown TT; Yuhas K; Mayer KH; Landovitz RJ; Marzinke MA; Hendrix CW; Chen YQ; Klingman KL; Chege W; Mccauley MB; Gulick RM; Wilkin TJ
    J Antimicrob Chemother; 2022 Feb; 77(2):500-506. PubMed ID: 34791296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco.
    Liu AY; Vittinghoff E; Sellmeyer DE; Irvin R; Mulligan K; Mayer K; Thompson M; Grant R; Pathak S; O'Hara B; Gvetadze R; Chillag K; Grohskopf L; Buchbinder SP
    PLoS One; 2011; 6(8):e23688. PubMed ID: 21897852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
    Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
    HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramuscular depot medroxyprogesterone acetate accentuates bone loss associated with tenofovir disoproxil fumarate-containing antiretroviral therapy initiation in young women living with HIV (the BONE: CARE study): a prospective cohort study in Uganda.
    Kiweewa Matovu F; Kiwanuka N; Nabwana M; Scholes D; Musoke P; Glenn Fowler M; Beksinska ME; Pettifor JM; Brown TT;
    Lancet Glob Health; 2022 May; 10(5):e694-e704. PubMed ID: 35427526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
    Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
    J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Less Bone Loss With Maraviroc- Versus Tenofovir-Containing Antiretroviral Therapy in the AIDS Clinical Trials Group A5303 Study.
    Taiwo BO; Chan ES; Fichtenbaum CJ; Ribaudo H; Tsibris A; Klingman KL; Eron JJ; Berzins B; Robertson K; Landay A; Ofotokun I; Brown T;
    Clin Infect Dis; 2015 Oct; 61(7):1179-88. PubMed ID: 26060295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
    Havens PL; Long D; Schuster GU; Gordon CM; Price G; Wilson CM; Kapogiannis BG; Mulligan K; Stephensen CB;
    Antivir Ther; 2018; 23(7):623-628. PubMed ID: 30260797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Harris DR; Price G; Baker A; Meyer WA; Wilson CM; Hazra R; Kapogiannis BG; Mulligan K;
    Clin Infect Dis; 2018 Jan; 66(2):220-228. PubMed ID: 29020329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of Glomerular Renal Function Decline in HIV-Uninfected Men and Women Discontinuing Emtricitabine-Tenofovir Disoproxil Fumarate Pre-Exposure Prophylaxis.
    Mugwanya KK; Wyatt C; Celum C; Donnell D; Kiarie J; Ronald A; Baeten JM;
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):374-80. PubMed ID: 26914909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
    Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY
    J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
    Glidden DV; Mulligan K; McMahan V; Anderson PL; Guanira J; Chariyalertsak S; Buchbinder SP; Bekker LG; Schechter M; Grinsztejn B; Grant RM
    Clin Infect Dis; 2018 Jul; 67(3):411-419. PubMed ID: 29415175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.